A previous study indicated that treatment with the GLP-1 agonist liraglutide (subcutaneously at a dose gradually titrated from 0.6 to 3 mg) in bipolar and mood disorder depression patients could result in an improvement in cognitive function and an alleviation of depressive pathological symptoms (Cuomo et al., 2018)
Both are dominated by mostly mild-to-moderate gastrointestinal effects, but the labeling differs
Jayaram S, Hariharan RS, Madhavan R, Periyandavar I, Samra SS
Degraded peptide fragments trigger immune responses that skew inflammation markers
You Do Not Sell Or Use Our Content Commercially Our work is free to share, but it may not be sold, monetized, or repurposed for commercial gain
A 12-month commitment is required, but the highly praised community approach drives strong member results